抗小鼠CTLA-4单抗(克隆号9D9) ，体内实验级重组，小鼠IgG2b Kappa | Syd Labs PA007380.m2b

描述

了解更多抗小鼠CTLA-4单克隆抗体（clone：9D9）引用文献，请查看：抗小鼠CTLA-4抗体（克隆号9D9）引用文献

抗小鼠CTLA-4单抗（9D9）参考文献:

1. Activity of murine surrogate antibodies for durvalumab and tremelimumab lacking effector function and the ability to deplete regulatory T cells in mouse models of cancer
Darren J. Schofield,et al.MAbs. 2021.PMCID: PMC7831362
“Preclinical studies of PD-L1 and CTLA-4 blockade have relied heavily on mouse syngeneic tumor models with intact immune systems, which facilitate dissection of immunosuppressive mechanisms in the tumor microenvironment. Commercially developed monoclonal antibodies (mAbs) targeting human PD-L1, PD-1, and CTLA-4 may not demonstrate cross-reactive binding to their mouse orthologs, and surrogate anti-mouse antibodies are often used in their place to inhibit these immune checkpoints. In each case, multiple choices exist for surrogate antibodies, which differ with respect to species of origin, affinity, and effector function. To develop relevant murine surrogate antibodies for the anti-human PD-L1 mAb durvalumab and the anti-human CTLA-4 mAb tremelimumab, rat/mouse chimeric or fully murine mAbs engineered for reduced effector function were developed and compared with durvalumab and tremelimumab. Characterization included determination of target affinity, in vivo effector function, pharmacokinetic profile, and anti-tumor efficacy in mouse syngeneic tumor models. Results showed that anti–PD-L1 and anti–CTLA-4 murine surrogates with pharmacologic properties similar to those of durvalumab and tremelimumab demonstrated anti-tumor activity in a subset of commonly used mouse syngeneic tumor models. This activity was not entirely dependent on antibody-dependent cellular cytotoxicity, antibody-dependent cellular phagocytosis effector function, or regulatory T-cell depletion, as antibodies engineered to lack these features showed activity in models historically sensitive to checkpoint inhibition, albeit at a significantly lower level than antibodies with intact effector function.”
2. Leukemic B Cell CTLA-4 Suppresses Co-stimulation of T cells
Priscilla Do,et al.J Immunol. 2019.PMCID: PMC6478536
“Clinical benefit of CTLA-4 blockade on T cells is known, yet the impact of its expression on cancer cells remains unaddressed. We define an immunosuppressive role for tumor expressed CTLA-4 using chronic lymphocytic leukemia (CLL) as a disease model. CLL, among other cancer cells, are CTLA-4+. Co-culture with activated human T cells induced surface CTLA-4 on primary human CLL B cells. CTLA-4 on CLL-derived human cell lines decreased CD80 expression on co-cultured CD80+ cells, with restoration upon CTLA-4 blockade. Co-culture of CTLA-4+ CLL cells with CD80-GFP+ cell lines revealed transfer of CD80-GFP into CLL tumor cells, similar to CTLA-4+ T cells able to trans-endocytose CD80. Co-culture of T cells with CTLA-4+ CLL cells decreased IL2 production. Using a human CTLA-4 knock-in mouse lacking FcγR function, anti-tumor efficacy was observed by blocking murine CTLA-4 on tumor cells in isolation of the T cell effect and Fc-mediated depletion. These data implicate tumor CTLA-4 in cancer cell-mediated immunosuppression in vitro and to have a functional role on tumor cells in vivo.”
3. A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy
Xuexiang Du,et al.Cell Res. 2018.PMCID: PMC5939050
“It is assumed that anti-CTLA-4 antibodies cause tumor rejection by blocking negative signaling from B7-CTLA-4 interactions. Surprisingly, at concentrations considerably higher than plasma levels achieved by clinically effective dosing, the anti-CTLA-4 antibody Ipilimumab blocks neither B7 trans-endocytosis by CTLA-4 nor CTLA-4 binding to immobilized or cell-associated B7. Consequently, Ipilimumab does not increase B7 on dendritic cells (DCs) from either CTLA4 gene humanized (Ctla4h/h) or human CD34+ stem cell-reconstituted NSG™ mice. In Ctla4h/m mice expressing both human and mouse CTLA4 genes, anti-CTLA-4 antibodies that bind to human but not mouse CTLA-4 efficiently induce Treg depletion and Fc receptor-dependent tumor rejection. The blocking antibody L3D10 is comparable to the non-blocking Ipilimumab in causing tumor rejection. Remarkably, L3D10 progenies that lose blocking activity during humanization remain fully competent in inducing Treg depletion and tumor rejection. Anti-B7 antibodies that effectively block CD4 T cell activation and de novo CD8 T cell priming in lymphoid organs do not negatively affect the immunotherapeutic effect of Ipilimumab. Thus, clinically effective anti-CTLA-4 mAb causes tumor rejection by mechanisms that are independent of checkpoint blockade but dependent on the host Fc receptor. Our data call for a reappraisal of the CTLA-4 checkpoint blockade hypothesis and provide new insights for the next generation of safe and effective anti-CTLA-4 mAbs.”

Syd Labs抗小鼠CTLA-4重组抗体（克隆号9D9），小鼠IgG2b Kappa（货号：PA007380.m2b）推荐同型对照抗体:

重组小鼠IgG2b同型对照抗体，体内实验级（In Vivo Grade Recombinant Mouse IgG2b Isotype Control Antibody）

Syd Labs相关重组IgG参考抗体（Related Recombinant IgG Reference Antibodies）:

重组小鼠IgG1同型对照抗体和突变体，体内实验级（In vivo Grade Recombinant Mouse IgG1 Isotype Control Antibody and Mutants）
重组小鼠IgG2a同型对照抗体和突变体，体内实验级（In vivo Grade Recombinant Mouse IgG2a Isotype Control Antibody and Mutants）
重组小鼠IgG2c同型对照抗体和突变体，体内实验级（In vivo Grade Recombinant Mouse IgG2c Isotype Control Antibody and Mutants）

Syd Labs提供以下研究级抗CTLA-4抗体生物类似药（research grade anti-CTLA-4 antibody biosimilars）:

Ipilimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody
Tremelimumab Biosimilar, research grade, anti-human CTLA-4 monoclonal antibody

Syd Labs提供以下重组CTLA-4蛋白（Recombinant CTLA-4 Proteins）:

Biotinylated Human CTLA-4 Protein
Cynomolgus CTLA-4 Protein
Human CTLA-4 Protein

Syd Labs提供以下体内实验级重组抗小鼠CTLA-4单克隆抗体(克隆号9D9)突变体:

体内实验级重组抗小鼠CTLA-4单克隆抗体，小鼠IgG2c-LALAPG Kappa(克隆号9D9)
体内实验级重组抗小鼠CTLA-4单克隆抗体，小鼠IgG2a-LALAPG Kappa(克隆号9D9)

请记住我们的产品信息: 体内实验级重组抗小鼠CTLA-4单克隆抗体，小鼠IgG2b Kappa(克隆号：9D9): PA007380.m2b Syd Labs In vivo Grade Recombinant Anti-mouse CTLA-4 Monoclonal Antibody, Mouse IgG2b Kappa (Clone: 9D9)。